Companies may face tighter regulation over promoting drugsBMJ 2004; 329 doi: https://doi.org/10.1136/bmj.329.7473.998-a (Published 28 October 2004) Cite this as: BMJ 2004;329:998
- David Spurgeon
The drug industry may be facing the same kind of sea change in business practices and regulation that other segments of corporate America faced in the wake of Enron and other corporate scandals, says an article in the New England Journal of Medicine (2004;351: 1891-900).
David Studdert and colleagues from the Harvard School of Public Health and Harvard Medical School say that the remarkable increase in regulatory, self regulatory, and prose-cutorial activity that currently focuses on conflicts of interest between doctors and drug companies will intensify.
Log in using your username and password
Log in through your institution
Register for a free trial to thebmj.com to receive unlimited access to all content on thebmj.com for 14 days.
Sign up for a free trial